FDA Drug Regulation & Scheduling Brief
Headline
DEA places O-desmethyltramadol in Schedule I effective August 12, 2026 through August 12, 2028
Executive Summary
The Drug Enforcement Administration placed O-desmethyltramadol (O-DSMT) in Schedule I of the Controlled Substances Act via a temporary scheduling order effective August 12, 2026. The order carries the full range of Schedule I controls, administrative, civil, and criminal sanctions, applicable to all persons who handle the substance.
Bottom Line
The DEA temporary scheduling order places O-desmethyltramadol in Schedule I effective August 12, 2026, and the order remains in force through August 12, 2028. All persons who handle O-DSMT in any covered capacity, including manufacture, distribution, import, export, possession, research, and chemical analysis, are subject to the full Schedule I control regime, including criminal sanctions, as of the effective date. DEA retains authority to extend the order for up to one additional year if permanent scheduling proceedings are initiated before expiration. Cresthaven reading: research institutions, chemical suppliers, and any entity with O-DSMT in inventory or in active study protocols face an immediate registration and compliance obligation under the Schedule I framework as of August 12, 2026.
Key Regulatory Signals
- Immediate Schedule I Controls Apply: The order is effective August 12, 2026. Any person who manufactures, distributes, imports, exports, possesses, or conducts research or chemical analysis with O-DSMT is now subject to Schedule I regulatory controls and associated administrative, civil, and criminal sanctions.
- Two-Year Duration With Extension Possibility: The temporary order runs through August 12, 2028. DEA retains authority to extend the temporary placement for up to one additional year if permanent scheduling proceedings are initiated before the order expires. DEA has stated it will publish any extension or permanent placement in the Federal Register.
- No Approved Drug Applications on Record: FDA confirmed to HHS as of June 11, 2025 that no investigational new drug applications or approved new drug applications for O-DSMT were on file. HHS raised no objection to the temporary placement. Cresthaven reading: any entity holding O-DSMT inventory or conducting O-DSMT research without a Schedule I registration faces immediate exposure under the order's effective date.
- Imminent Hazard Finding Bypasses Standard Scheduling Review: DEA invoked its authority to act without the standard evaluation process by finding that temporary placement is necessary to avoid an imminent hazard to public safety. This finding, not a standard scheduling review, is the legal basis for the order's immediate effect.
Regulatory Delta
- DEA invoked its imminent-hazard temporary scheduling authority for O-DSMT, following the same procedural path used for other novel opioid analogs in recent years, including prior tramadol-class derivatives.
- The order covers O-DSMT in all chemical forms: isomers, esters, ethers, salts, and salts of those isomers, esters, and ethers. The scope extends beyond a single compound.
- No pending Congressional legislation or cross-agency rulemaking specific to O-DSMT has been identified. The action operates entirely under existing temporary scheduling authority in the Controlled Substances Act.
Materiality Classification
HIGH — The order is a temporary scheduling order with an effective date of August 12, 2026, imposing Schedule I controls and criminal sanctions on all persons who handle O-desmethyltramadol, a population that extends across research institutions, chemical suppliers, and distributors beyond any single named respondent.
Time Horizon
sunset — 2028-08-12
Intelligence Outlook
Monitor the DEA Federal Register notices and this docket for initiation of permanent scheduling proceedings or an extension order before August 12, 2028.